文章核心观点 - 一款由阿斯利康公司开发的乳腺癌药物在三期临床试验中未能达到统计学显著性,即未能显著延长患者的生存期[1] - 这是阿斯利康本月内第二个三期临床试验失败的药物[1] - 该药物的监管前景存在不确定性,阿斯利康表示将向监管机构提交新的数据[3] 根据相关目录分别进行总结 公司层面 - 阿斯利康的美国存托凭证股价在周一交易中下跌超过1%,但全年仍有上涨[2] - 阿斯利康表示将向监管机构提交新的临床试验数据[3] - 阿斯利康肿瘤研发部门执行副总裁表示,近年来乳腺癌治疗领域取得了显著进步,新的临床试验结果和之前的积极结果显示了该药物的临床价值[3] 行业层面 - 该药物正在与日本制药公司第一三共共同开发[3] - 该三期临床试验包括了700多名无法手术或转移性乳腺癌患者[1][3] - 分析师表示,新的临床试验数据使该药物获批的可能性降低[3]

文章核心观点 - 公司最近一个交易日的股价下跌0.66%,低于标普500指数的0.19%下跌 [1] - 公司过去一个月的股价下跌8.14%,低于医疗行业1.44%的涨幅和标普500指数2.06%的涨幅 [1] - 公司即将发布的财报中,预计每股收益将同比增长22.99%,收入将同比增长14.37% [1] - 全年来看,分析师预计公司每股收益和收入将分别同比增长11.57%和14.55% [2] - 分析师对公司的预测修正情况与公司未来股价表现有直接关系 [2] 根据目录分别总结 公司财务表现 - 公司最近一个交易日的股价下跌0.66%,低于标普500指数的0.19%下跌 [1] - 公司过去一个月的股价下跌8.14%,低于医疗行业1.44%的涨幅和标普500指数2.06%的涨幅 [1] - 公司即将发布的财报中,预计每股收益将同比增长22.99%,收入将同比增长14.37% [1] - 全年来看,分析师预计公司每股收益和收入将分别同比增长11.57%和14.55% [2] 分析师预测 - 分析师对公司的预测修正情况与公司未来股价表现有直接关系 [2] - 公司目前的Zacks评级为3级(持有) [3] 估值情况 - 公司目前的市盈率为19.47倍,高于行业平均水平15.96倍 [3] - 公司的PEG率为1.49,低于行业平均水平1.69 [3] 行业情况 - 公司所属的大型制药行业目前在250多个行业中排名前33% [4] - 排名前50%的行业相比后50%的行业平均表现要好2倍 [4]

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?Let's take a look at what these Wall Street heavyweights have to say about Astrazeneca (AZN) before we discuss the reliability of brokerage recommendations and how to use them to your advantage.Astrazeneca currently has an average brokerage recommendation ...

AstraZeneca (AZN) announced that the FDA has approved its marketed asthma drug, Fasenra (benralizumab) for a new indication. The regulatory body has now approved Fasenra for treating adult patients with eosinophilic granulomatosis with polyangiitis (“EGPA”).EGPA is a rare autoimmune disease that can cause damage to multiple organs and tissues and is the second approved indication for Fasenra.Fasenra is already approved as an add-on maintenance treatment for severe eosinophilic asthma (SEA).Shares of AstraZe ...

AstraZeneca PLC (NASDAQ:AZN) Meet the Management at ESMO 2024 Conference September 16, 2024 2:00 PM ET Company Participants Pascal Soriot - Chief Executive Officer Susan Galbraith - EVP, Oncology R&D Thomas Powles - Professor of Genitourinary Oncology; Director, Barts Cancer Centre Sunil Verma - SVP, Global Head, Oncology Franchise Dave Fredrickson - EVP, Oncology Business Matt Hellmann - VP, Early Oncology Development Cristian Massacesi - Chief Medical Officer, Chief Development Officer Oncology Melissa Sc ...

会议主要讨论的核心内容 - 公司在2030年实现80亿美元收入的雄心勃勃的目标 [8][9][10] - 公司正在投资多项新兴技术,包括抗体偶联药物(ADC)、双特异性免疫检查点抑制剂等,以塑造未来医疗的发展方向 [10][11][12] - 公司在肿瘤治疗领域的目标是通过联合用药和序贯治疗来实现治愈癌症的目标 [11][12] - 公司正在开发新的诊断技术,如QCS生物标志物,以实现更精准的靶向治疗 [12][23][24] 问答环节重要的提问和回答 - 针对TROPION-Lung01的申请,公司是否会将QCS生物标志物数据重新提交FDA审核 [104][105] - 公司如何看待NIAGARA试验与其他膀胱癌免疫治疗试验(如CheckMate 247和AMBASSADOR)的比较 [50][51][52][53][54] - 公司如何评估QCS生物标志物在Dato-DXd乳腺癌研究中的作用 [129][131][132] - 公司为何在TL01结果复杂的情况下,仍决定启动更多Dato-DXd的III期试验 [134][135][136][137][138][139] - 公司对2030年在肺癌和乳腺癌领域的市场份额目标是什么 [148][149][150][151][152] - 公司如何看待NIAGARA试验的可批准性,特别是在AEGEAN试验讨论的背景下 [156][157][158][159]

Biopharmaceutical stock AstraZeneca PLC (NASDAQ:AZN) is 1.3% lower before the open, after a bear note from Deutsche Bank. The analyst downgraded AZN to "sell" from "hold" and lowered its price target, pointing to the company's results from a lung cancer trial that showed its experimental precision drug did not improve overall survival.Coming into today, most analysts were bullish on AstraZeneca stock. Of the 14 in coverage, 11 rated it a "buy" or better, and the 12-month average target price of $90.89 is a ...

thelinke/E+ via Getty Images Shares of AstraZeneca (NASDAQ:AZN) declined earlier this week after the company and its partner Daiichi Sankyo (OTCPK:DSNKY) presented disappointing overall survival data from the phase 3 trial of the antibody-drug conjugate (‘ADC’) candidate datopotamab deruxtecan, or Dato-DXd, in patients with advanced non-squamous non-small cell lung cancer. Dato-DXd is part of AstraZeneca’s expanding ADC pipeline, and part of a greater effort to offer better treatment options for lung ca ...

文章核心观点 - AstraZeneca的实验性肺癌药物datopotamab deruxtecan在III期临床试验中未能显著提高患者的总生存率 [1] - 该药物本旨在治疗转移性非小细胞肺癌,但试验结果显示总生存率"未达到统计学意义" [1] - AstraZeneca股价在消息公布后有所下跌,但随后有所回升 [1] 行业概况 - 目前docetaxel是成人晚期或转移性非鳞状非小细胞肺癌的标准化疗药物 [2] - 尽管业界一直努力寻求超越docetaxel的新疗法,但患者的平均生存期仍只有约1年 [2] 公司概况 - AstraZeneca与日本大日本三共公司共同开发了该实验性肺癌药物 [1] - AstraZeneca股价自年初以来已上涨超过20% [1]

The companies commit to bring cutting-edge liquid biopsy testing to 20 institutions globally over the next 12 monthsBOSTON and ROLLE, Switzerland, Sept. 10, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced a new milestone in the global introduction of the liquid biopsy test MSK-ACCESS® powered with SOPHiA DDM™, first announced in October 2023. Under a definitive partnership agreement with AstraZenec ...